同种异体半相合细胞因子诱导的杀伤细胞治疗晚期肝癌的疗效及安全性评估

Curative effect and safety of haploidentical allogeneic cytokine-induced killer in treatment of advanced hepatocellular carcinoma

  • 摘要:
      目的  探讨同种异体半相合细胞因子诱导的杀伤(CIK)细胞治疗晚期肝癌的疗效及安全性。
      方法  采集21例晚期肝细胞癌(肝癌)患者健康一级直系亲属的外周血单个核细胞, 在体外诱导成异体半相合CIK细胞后回输给患者, 回输4个周期。评估治疗效果和安全性。
      结果  随访半年, 21例患者的存活率为81%(17/21), 疾病稳定患者11例, 疾病进展患者10例(含4例死亡病例)。6例患者治疗期间出现不同程度的发热, 1例出现皮疹。与治疗前相比, 患者治疗后第4周期的血小板数量降低, 差异有统计学意义(P < 0.05), 而患者治疗后第1、4周期的白细胞、中性粒细胞、淋巴细胞、血红蛋白, 肝、肾功能差异均无统计学意义(均为P>0.05)。
      结论  同种异体半相合CIK细胞治疗晚期肝癌患者能够有效改善生活质量, 不良反应大都在可耐受范围, 是一种较安全的治疗方法。

     

    Abstract:
      Objective  To investigate the curative effect and safety of haploidentical allogeneic cytokine-induced killer (CIK) in treatment of advanced hepatocellular carcinoma.
      Methods  The peripheral blood mononuclear cell (PBMC) of the healthy immediate family members of 21 patients with advanced hepatocellular carcinoma (HCC) were collected, induced into haploidentical allogeneic CIK in vitro and transfused to the patients for 4 cycles. The curative effect and safety were assessed.
      Results  The 21 patients were followed up for half a year. The survival rate was 81% (17/21). Among the 21 patients, 11 cases were with stable disease and 10 cases were with progressive disease(including 4 dead cases). Six patients developed fever of different degrees during the treatment and one patient developed rash. The platelet counts of the patients at the fourth cycle after the treatment decreased compared with that before the treatment, with significance difference (P < 0.05). The difference in leukocytes, neutrophils, lymphocytes, hemoglobin, liver function and renal function at the first and fourth cycle after the treatment had no statistical significance (all in P>0.05).
      Conclusions  Haploidentical allogeneic CIK in treatment of advanced HCC may effectively improve the quality of life and the adverse reactions are tolerable, which is a relatively safe therapy.

     

/

返回文章
返回